Ozempic Cost in Washington (2026): Prices, Insurance, and Savings Options

What Ozempic Actually Costs at Washington Pharmacies in 2026

The retail cash price for Ozempic at Washington pharmacies sits at $998 per month in 2026, matching Novo Nordisk's national list price. That figure applies to all four pen strengths (0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg) because each box contains a one-month supply of prefilled pens dosed for weekly injection.

Prices vary only modestly between pharmacy chains across the state. A patient filling at a Costco in Seattle or a Rite Aid in Spokane will encounter roughly the same sticker price, because Novo Nordisk sets a uniform wholesale acquisition cost (WAC). The real price differences emerge through insurance benefit design, manufacturer coupons, and alternative formulations.

Semaglutide was first approved by the FDA in December 2017 for type 2 diabetes under the brand name Ozempic, with the prescribing information specifying subcutaneous injection at 0.25 mg for initiation, titrating to 0.5 mg or 1.0 mg for maintenance. The 2.0 mg dose was added later. In SUSTAIN-7 (N=1,201), semaglutide 0.5 mg reduced HbA1c by 1.5% at 40 weeks compared with dulaglutide 0.75 mg, which achieved 1.1% (Pratley et al., 2018). That trial also showed a 4.6 kg mean weight loss with semaglutide 0.5 mg versus 2.3 kg with dulaglutide 0.75 mg.

These numbers matter for Washington patients weighing cost against efficacy. A drug that produces greater glycemic control and weight reduction per dollar spent changes the value calculation, particularly for patients navigating prior authorization requirements or considering alternatives.

Washington Medicaid Coverage for Ozempic

Washington Apple Health (Medicaid) covers Ozempic with prior authorization for its FDA-approved indication of type 2 diabetes. The state's Health Care Authority (HCA) manages the preferred drug list, and semaglutide has maintained coverage since its formulary addition, though prescribers must document that the patient meets specific clinical criteria.

Prior authorization typically requires evidence that the patient has tried and failed metformin (or has a contraindication to it), a current HbA1c above a plan-defined threshold (often 7.0% or higher), and a diagnosis of type 2 diabetes. Off-label prescribing for weight management alone does not qualify for Medicaid reimbursement in Washington under current policy. The Endocrine Society's 2024 clinical practice guideline recommends GLP-1 receptor agonists as second-line therapy after metformin, a recommendation that aligns with Washington HCA's authorization criteria.

Processing times for Medicaid prior authorization in Washington run 3 to 7 business days. Denials can be appealed, and the HCA publishes specific appeal instructions on its pharmacy benefits page. Patients who are denied may qualify for compounded semaglutide as a lower-cost alternative while pursuing the appeal.

One practical note: Washington expanded Medicaid eligibility under the ACA, meaning the income threshold for adults sits at 138% of the federal poverty level. This makes a larger share of Washington residents eligible for Apple Health coverage of Ozempic compared with states that did not expand.

Commercial Insurance Coverage in Washington

Most major commercial insurers operating in Washington, including Premera Blue Cross, Regence BlueShield, Molina Healthcare, and Kaiser Permanente of Washington, include Ozempic on their formularies for type 2 diabetes. Coverage terms vary by plan tier.

Preferred formulary placement means lower copays, typically $30 to $75 per month for patients on mid-tier plans. Non-preferred placement pushes copays to $100 to $250, and some high-deductible health plans require the patient to pay the full $998 until meeting the deductible. The American Diabetes Association's Standards of Care (2024) emphasizes that cost should not be a barrier to evidence-based diabetes pharmacotherapy, a position that some Washington insurers cite in their coverage rationale for GLP-1 receptor agonists.

Step therapy is common. Many plans require documented metformin use (or intolerance) before approving semaglutide. Some also require trial of a sulfonylurea or SGLT2 inhibitor. Washington state law (RCW 48.43.400) provides a process for patients and prescribers to request step-therapy exceptions when clinically appropriate.

For patients with employer-sponsored coverage, checking the specific formulary before filling a prescription prevents billing surprises. The plan's pharmacy benefits manager (PBM), not the insurer's medical policy, determines the actual out-of-pocket cost.

Compounded Semaglutide in Washington: Legality and Pricing

Compounded semaglutide is legal in Washington when dispensed by a licensed 503A compounding pharmacy with a valid patient-specific prescription. These pharmacies operate under state Board of Pharmacy oversight and must comply with USP 797 sterile compounding standards. The price point is significantly lower: approximately $199 per month compared with $998 for brand-name Ozempic.

The FDA's position on compounded semaglutide has evolved. In October 2023, the FDA placed semaglutide on the drug shortage list, which triggered Section 503A compounding permissions. As of early 2025, semaglutide was removed from the shortage list, creating regulatory uncertainty. However, 503A pharmacies in Washington continue to compound semaglutide under patient-specific prescriptions, citing state-level pharmacy law that permits compounding of commercially available drugs when a prescriber documents a clinical need for a customized formulation.

Dr. Robert Califf, former FDA Commissioner, stated during a 2024 Senate hearing: "The compounding of GLP-1 receptor agonists raises quality and safety questions that patients and prescribers must weigh carefully against cost considerations."

Washington patients considering compounded semaglutide should verify three things. First, that the pharmacy holds a current Washington State Board of Pharmacy license. Second, that the pharmacy provides certificates of analysis (COAs) for potency and sterility on each batch. Third, that their prescriber is willing to write for a compounded formulation and monitor them appropriately.

The cost difference between $998 and $199 per month ($9,588 annual savings) makes compounded semaglutide appealing, but the trade-off is the absence of Novo Nordisk's standardized manufacturing, FDA lot-by-lot release testing, and the autoinjector pen delivery system. Compounded versions typically come in vials requiring manual syringe drawing.

The Novo Nordisk Savings Card and Other Discount Programs

Novo Nordisk offers a savings card for Ozempic that can reduce monthly out-of-pocket costs to as low as $25 for commercially insured patients. The card is not available to patients on Medicare, Medicaid, Tricare, or other government-funded programs.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Ozempic, and the savings card covers the difference between the plan's copay and $25, up to a maximum benefit per fill and per calendar year. The annual cap has historically been $150 per month ($1,800 per year), though Novo Nordisk adjusts terms periodically.

For uninsured Washington patients paying the full $998, the savings card does not apply. Instead, Novo Nordisk's Patient Assistance Program (PAP) may provide Ozempic at no cost to patients who meet income criteria (typically below 400% of the federal poverty level). Application requires income documentation and prescriber certification.

Additional discount pathways available to Washington residents include pharmacy discount cards (GoodRx, RxSaver, SingleCare), which occasionally offer prices below $900 but rarely drop below $800 for brand-name Ozempic. Mark Cuban's Cost Plus Drugs does not currently stock injectable semaglutide. Some Washington patients have reported success negotiating cash-pay rates directly with independent pharmacies, particularly in rural areas with lower overhead.

A 2023 analysis published in JAMA Internal Medicine found that out-of-pocket costs for GLP-1 receptor agonists were the single strongest predictor of medication discontinuation at 12 months, with patients paying more than $50 per month showing 2.3 times the discontinuation rate of those paying under $50 (Dhruva et al., 2023). This finding underscores why cost navigation matters for Washington patients starting Ozempic.

Telehealth Prescribing of Ozempic in Washington

Washington permits telehealth prescribing of Ozempic statewide. The state's telehealth parity law (RCW 48.43.735) requires insurers to cover telehealth-delivered services at the same rate as in-person visits, which includes prescribing and managing GLP-1 receptor agonist therapy.

Telehealth platforms operating in Washington must use prescribers licensed by the Washington Medical Commission or the Washington State Department of Health (for nurse practitioners and physician assistants with prescriptive authority). Semaglutide is a Schedule VI prescription drug in Washington, meaning no DEA scheduling restrictions apply to telehealth prescribing.

Several telehealth-first platforms now serve Washington patients for GLP-1 prescribing, including HealthRX. The typical workflow involves a video or asynchronous consultation, lab review (recent HbA1c or metabolic panel), prescription transmission to a pharmacy of the patient's choice, and ongoing dose titration management. Costs for the telehealth visit itself range from $0 (insurance-billed) to $99 to $199 (cash-pay consultation), separate from the medication cost.

Rural Washington counties, such as Ferry, Pend Oreille, and Garfield, benefit particularly from telehealth access. These areas have fewer endocrinologists and obesity medicine specialists per capita, and the Washington State Medical Association has acknowledged that telehealth reduces geographic barriers to specialty prescribing.

How to Lower Your Ozempic Cost in Washington: A Step-by-Step Approach

Start with insurance verification. Call the number on the back of your insurance card and ask specifically: "Is semaglutide (Ozempic) on my formulary, and what tier is it?" Request the prior authorization criteria in writing.

If your plan covers Ozempic, ask your prescriber to submit prior authorization with documentation of your HbA1c, BMI, prior medication trials, and any comorbidities. The more complete the clinical documentation, the higher the approval rate. A 2022 study in Diabetes Care found that 68% of initial GLP-1 receptor agonist prior authorizations were approved when submitted with full clinical documentation versus 41% with incomplete submissions (Fralick et al., 2022).

If approved, apply for the Novo Nordisk savings card at novocare.com. This can reduce your copay to $25 per month if you carry commercial insurance.

If denied, file a formulary exception request citing medical necessity. Washington insurance code gives you the right to an expedited review within 72 hours for urgent cases. Simultaneously ask your prescriber about compounded semaglutide from a licensed 503A pharmacy as a bridge while the appeal processes.

If uninsured, compare three options: Novo Nordisk's PAP (free if you qualify by income), compounded semaglutide at approximately $199 per month, and pharmacy discount cards for brand-name Ozempic. For most uninsured patients in Washington, compounded semaglutide offers the best price-to-access ratio.

The Endocrine Society's clinical practice guideline recommends that clinicians "assess medication affordability at each visit and adjust therapy when cost threatens adherence" (Garvey et al., 2024). This is practical advice. Discuss cost openly with your prescriber.

Washington-Specific Factors Affecting Ozempic Access

Washington's regulatory environment creates both advantages and friction points for patients seeking Ozempic. On the advantage side, the state's Medicaid expansion provides broader eligibility, telehealth parity law ensures remote access, and the Board of Pharmacy permits 503A compounding.

On the friction side, Washington has no state-level prescription drug price cap legislation as of 2026. The Prescription Drug Affordability Board (PDAB), established by SB 5532 in 2019, has authority to conduct cost reviews and set upper payment limits on certain drugs, but GLP-1 receptor agonists have not yet been subject to an upper payment limit determination. The PDAB completed its first round of drug affordability reviews in 2024, focusing on insulin products.

Washington's 340B program participation also affects pricing. Patients treated at federally qualified health centers (FQHCs) and other 340B-eligible entities across the state may access Ozempic at significantly reduced prices through 340B contract pharmacy arrangements. Washington has over 30 FQHC organizations with 340B eligibility, concentrated in King, Pierce, Snohomish, and Spokane counties.

The CDC's National Diabetes Statistics Report estimates that 10.2% of Washington adults have diagnosed diabetes, slightly below the national average of 11.6%. This means approximately 590,000 Washington residents carry a diabetes diagnosis, with a substantial portion potentially eligible for GLP-1 receptor agonist therapy.

Comparing Ozempic to Alternatives Available in Washington

Ozempic is not the only GLP-1 receptor agonist available to Washington patients. Trulicity (dulaglutide) carries a list price of approximately $1,032 per month but has broader formulary placement on some Washington plans. Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, lists at approximately $1,023 per month and has shown superior glycemic control in head-to-head data.

In SUSTAIN-7, semaglutide 1.0 mg reduced HbA1c by 1.8% versus 1.4% for dulaglutide 1.5 mg at 40 weeks (Pratley et al., 2018). The weight loss difference was also clinically meaningful: 6.5 kg with semaglutide 1.0 mg versus 3.0 kg with dulaglutide 1.5 mg.

Rybelsus (oral semaglutide) offers the same active molecule in tablet form at a list price of approximately $936 per month. Some Washington patients prefer oral dosing, though bioavailability is lower and the fasting requirement (30 minutes before food, with no more than 4 ounces of water) can be inconvenient.

For patients whose primary goal is weight management rather than glycemic control, Wegovy (semaglutide 2.4 mg) is the FDA-approved option, but its list price of approximately $1,349 per month and more restrictive insurance coverage in Washington make Ozempic's off-label use a common workaround. Washington Medicaid does not cover Wegovy for weight management as of 2026.

The choice between these agents should be guided by the patient's clinical profile, insurance formulary, and out-of-pocket cost, discussed with their prescriber at initiation and reassessed at each dose titration visit.